Safety of Intramyocardial Stem Cell Therapy for the Ischemic Myocardium: Results of the Rostock Trial after 5-Year Follow-Up

Cell Transplantation

Article

Alexander Kaminski¹  Can Yerebakan¹  Andreas Liebold¹  Gustav Steinhoff¹ 

[1] Department of Cardiac Surgery, University of Rostock, Rostock, Germany;

关键词: Stem cells;    Myocardial regeneration;    Myocardial ischemia;    Cardiac surgery;    Heart failure;   

DOI  :  10.3727/096368907783338280

来源: Sage Journals

【 摘 要 】

Stem cell treatment for acute or chronic ischemic myocardium has gained major attention in the last decade. Experimental and clinical studies have shown evidence for functional improvement after cell-based treatments in acute or chronically ischemic jeopardized myocardium. Since 2001 we have performed bone marrow-derived CD133+ stem cell transplantations with concomitant coronary artery bypass surgery. Although our focus is mainly on the functional results of the stem cell treatment, possible long-term side effects of the new therapeutic strategy should also be addressed. Here we present for the first time the long-term follow-up safety results of the Rostock trial after direct intramyocardial stem cell treatment in 32 patients.

【 授权许可】

Unknown   
© 2007 Cognizant Comm. Corp.